ECM
SPRO icon

Endurant Capital Management’s Spero Therapeutics SPRO Stock Holding History

Endurant Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,100
Closed -$365K – 81
2017
Q4 		$365K Buy
+31,100
New +$382K 0.11% 73

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Endurant Capital Management's SPRO Position: Q1 2018 in Review

Endurant Capital Management sold out of Spero Therapeutics (SPRO) in Q1 2018, closing a stake of 31,100 shares — an estimated $365K sold.

Endurant Capital Management first reported a position in SPRO in Q4 2017 and held it in 1 quarter. The position peaked at $365K in Q4 2017. 35 funds tracked by Wall St. Rank hold SPRO as of Q1 2018.

  • Endurant Capital Management reported no remaining Spero Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Endurant Capital Management sold 31,100 Spero Therapeutics shares in Q1 2018, an estimated $365K.
  • Endurant Capital Management first reported a position in Spero Therapeutics in Q4 2017 and held it in 1 quarter.
  • Endurant Capital Management's Spero Therapeutics position peaked at $365K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2018.

Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.